1f
12
9
1a
8
20
8
49
16
8
19
1
49
2
8
1b
1d
18
89
34
1d
2 29
1d
25
34
Mary Ann Thenganatt, MD
49Penn Medicine Clinician of Neurology
7
60
Department: Neurology
4
1
b
1d
46
Contact information
5a
4
3
3
3
2
4
b
1f
5a
330 S. 9TH STREET
PHILADELPHIA, PA 19107
26
PHILADELPHIA, PA 19107
35
f
13
Education:
21 b BA, MD 26 (Medical Science, Medicine) c
2a Boston University, 2006.
c
3
3
21
21 b BA, MD 26 (Medical Science, Medicine) c
2a Boston University, 2006.
c
1f
Post-Graduate Training
24 4c Intern, Internal Medicine, UCLA Medical Center, 2006-2007.
24 55 Resident, Neurology, Columbia University Medical Center, 2007-2010.
24 66 Movement Disorders Fellow, Neurology, Columbia University Medical Center, 2010-2012.
c
3
25
24 4c Intern, Internal Medicine, UCLA Medical Center, 2006-2007.
24 55 Resident, Neurology, Columbia University Medical Center, 2007-2010.
24 66 Movement Disorders Fellow, Neurology, Columbia University Medical Center, 2010-2012.
c
17
Certifications
28 43 American Board of Psychiatry and Neurology, 2010.
c
3
8d
Permanent link28 43 American Board of Psychiatry and Neurology, 2010.
c
2 29
21
1e
1d
24
2b
29
27
23
a4 Thenganatt MA, Jankovic J: Psychogenic Parkinsonism. Functional Neurological Disorders, Handbook of Neurology 2a 2016 Notes: In press.
f1 Thenganatt MA, Jankovic J: Botulinum toxin therapy for cervical dystonia. Treatment of Dystonia. Dressler D, Altenmuller E and Krauss J (eds.). 2016 Notes: In progress.
8d Thenganatt MA, Jankovic J: Recent advances in understanding/managing Tourette’s Syndrome 33 F1000Res 592, August 2015.
a9 Thenganatt MA, Jankovic J: Psychogenic movement disorders. Neurol Clin 33(1): 205-224, Feb 2015.
a6 Thenganatt MA, Jankovic J : Parkinson Disease Subtypes. JAMA Neurol 71(4): 499-504, Apr 2014.
a6 Thenganatt MA, Jankovic J : Treatment of dystonia. Neurotherapeutics 11(1): 139-52, Jan 2014.
d4 Thenganatt MA, Louis ED: Personality profile in essential tremor: A case- control study. Parkinsonism Relat Disord 18(9): 1042-4, Nov 2012.
f3 Thenganatt MA, Louis ED: Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Rev Neurother 12(6): 687-96, Jun 2012.
cb Botulinum toxin for the treatment of movement disorders: Thenganatt MA, Fahn S. Curr Neurol Neurosci Rep 12(4): 399-409, Aug 2012.
2c
7
1d
1f
Selected Publications
db Thenganatt MA, Jankovic J: The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord Suppl 1: S162-5, Jan 2016.a4 Thenganatt MA, Jankovic J: Psychogenic Parkinsonism. Functional Neurological Disorders, Handbook of Neurology 2a 2016 Notes: In press.
f1 Thenganatt MA, Jankovic J: Botulinum toxin therapy for cervical dystonia. Treatment of Dystonia. Dressler D, Altenmuller E and Krauss J (eds.). 2016 Notes: In progress.
8d Thenganatt MA, Jankovic J: Recent advances in understanding/managing Tourette’s Syndrome 33 F1000Res 592, August 2015.
a9 Thenganatt MA, Jankovic J: Psychogenic movement disorders. Neurol Clin 33(1): 205-224, Feb 2015.
a6 Thenganatt MA, Jankovic J : Parkinson Disease Subtypes. JAMA Neurol 71(4): 499-504, Apr 2014.
a6 Thenganatt MA, Jankovic J : Treatment of dystonia. Neurotherapeutics 11(1): 139-52, Jan 2014.
d4 Thenganatt MA, Louis ED: Personality profile in essential tremor: A case- control study. Parkinsonism Relat Disord 18(9): 1042-4, Nov 2012.
f3 Thenganatt MA, Louis ED: Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Rev Neurother 12(6): 687-96, Jun 2012.
cb Botulinum toxin for the treatment of movement disorders: Thenganatt MA, Fahn S. Curr Neurol Neurosci Rep 12(4): 399-409, Aug 2012.
2c